The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Internet Marketing Group, Inc., a Tennessee Corporation; et al.
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.
There is a related federal proceeding and two related administrative proceedings:
USA BEVERAGES, Inc., a Florida corporation and New Mexico corporation; DILRAJ MATHAUDA a/k/a Dan Reynolds, individually and as a principal of USA Beverages, Inc.; SIRTAJ MATHAUDA, individually and as a principal of USA Beverages, Inc.; JEFF PEARSON
Vend Direct, Inc. and Gary Luckner., United States of America (for the FTC)
National Vending Consultants, Inc., Success Vending Group, Inc., USA Candy Express, Inc.,et al.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Statement of Regulatory Priorities
0612006 Informal Interpretation
0602005 Informal Interpretation
Barr Pharmaceuticals, Inc., In the Matter of
The consent order settles charges that Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion would have eliminated current or future competition between Barr and Pliva in certain markets for generic pharmaceuticals treating depression, high blood pressure and ruptured blood vessels, and in the market for organ preservation solutions. In settling the Commission’s charges, Barr is required to sell its generic antidepressant trazodone and its generic blood pressure medication triamterene/HCTZ. Barr also is required to divest either Pliva’s or Barr’s generic nimodipine for use in treating ruptured blood vessels in the brain. Finally, Barr is required to divest Pliva’s branded organ preservation solution Custodial.